echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > No need to consider the approval of Bristol Myers Squibb inhibitor for PD-L1 expression

    No need to consider the approval of Bristol Myers Squibb inhibitor for PD-L1 expression

    • Last Update: 2020-06-19
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit
    From: immediate medical news < br / > Bristol Myers Squibb (BMS) recently announced that its heavyweight PD-1 inhibitor, opdivo (nivolumab), has been approved by the US FDA to treat advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) patients who are unresectable after chemotherapy with fluorouracil and platinum drugs, regardless of the expression level of tumor PD-L1< br / > esophageal cancer is a kind of digestive tract tumor that starts from the inner layer of esophagus (i.emucosa) and grows continuouslySquamous cell carcinoma is a cancer caused by the normal lining of mucosaFor about 25% of patients, the disease is only diagnosed in the late stage, when the treatment options for patients are very limited< br / > this approval is based on the results of a phase 3 clinical trial, attraction-3, in which opdivo (n = 210) showed better overall survival (OS) than paclitaxel chemotherapy (n = 209) (HR = 0.77; 95% CI: 0.62-0.96; P = 0.0189)The median OS was 10.9 months (95% CI: 9.2-13.3) in the opdivo group and 8.4 months (95% CI: 7.2-9.9) in the docetaxel or paclitaxel group< br / > "many cases of esophageal cancer are diagnosed at an advanced stage, which can have a significant impact on the health of patientsOnce patients with advanced esophageal squamous cell carcinoma progress, their treatment options will be limited, "said DrAdam lenkowsky, head of cardiovascular tumor immunity Department of Bristol Myers Squibb." opdivo, as a new treatment option, has been approved for use in patients with previous treatment of advanced esophageal squamous cell carcinoma, regardless of the expression of PD-L1, Highlighting our commitment to providing new options to address the unmet needs of patients, and moving us closer to understanding the full potential of immunotherapy for gastrointestinal cancer" < br / > original title: express delivery | no need to consider the expression of PD-L1, Bristol Myers Squibb PD-1 inhibitor is approved for the treatment of advanced esophageal squamous cell carcinoma < br / >
    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.